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Background: Clomiphene citrate (CC) is most commonly used as a first-line treatment of infertility. However, a
disturbance of endometrial growth by the adverse effects of the CC has been recognized. Since a thin endometrium
is recognized as a critical factor of implantation failure, preventing CC-induced thinning of the endometrium is
important. This study was undertaken to investigate whether the modified CC treatments are useful to prevent a thin
endometrium in patients undergoing CC treatments.
Methods: This study is a prospective, randomized controlled study. The study was performed at the Saiseikai
Shimonoseki General Hospital during a 4-month period (May 2012 to September 2012). Sixty-six infertile women who
had a thin endometrium (< 8 mm) during the standard CC treatment (50 mg/day on days 5–9 of the menstrual cycle)
were enrolled. The patients were randomly divided into three groups: 22 patients were given 25 mg/day CC on days
5–9 (half-dose group), 22 patients were given 50 mg/day CC on days 1–5 (early administration group) and 22 patients
received a standard CC treatment again (control group). Endometrial thickness at the induction of ovulation was
assessed by ultrasonography. The primary endpoint of this study was an endometrial thickness.
Results: Half dose administration and early administration improved the endometrial thickness (≥ 8 mm) in 14 patients
(70%) and in 19 patients (90%) respectively, while only 3 patients (15%) improved in endometrial thickness in the
control group. The mean endometrial thickness was also significantly higher in the half dose group (8.6 ± 1.5 mm) and
early administration group (9.4 ± 1.5 mm) compared to the control group (6.7 ± 1.8 mm). No side effect was observed
in this study.
Conclusions: The modified treatment with a half-dose or early administration of CC significantly increased endometrial
thickness in patients with a history of thin endometrium caused by the standard CC regimen. The modified CC treatments
in this study can be beneficial for patients with a thin endometrium as a result of standard CC treatment.
Trial registration: Clinical Trial Registration Number: UMIN000007959.
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Clomiphene citrate (CC) has been widely used to stimu-
late follicular growth in the treatment of infertility.
CC has an antiestrogenic effect on the hypothalamus
by binding to estrogen receptors. This stimulates a
gonadotropin-releasing hormone (GnRH) pulse that
induces gonadotropin secretion from the anterior pituitary
gland. CC is most commonly used as a first-line treatment
of infertility [1,2]. However, several adverse effects of the
CC treatment have been recognized. One of them is a
disturbance of endometrial growth by the antiestro-
genic effect. In fact, endometrial thickness is signifi-
cantly thinner in women taking CC than women not
taking CC [3-5]. Since a thin endometrium is recog-
nized as a critical factor of implantation failure [6-9],
preventing CC-induced thinning of the endometrium
is important.
Since the endometrium grows by estrogen during
the follicular phase, endometrial growth is impaired
by antiestrogenic effects of CC [10]. Impaired epithelial cell
proliferation and delayed glandular maturation are often
found in endometrial biopsies from patients treated with
CC [11]. Some reports also indicate that the number and
diameter of the gland were lower in the CC treatment cycle
than in the control cycle [12]. These results strongly suggest
that a thin endometrium caused by the CC treatment
is due to impaired endometrial growth and that this
is a major cause of poor pregnancy rates in women
who showed a thin endometrium by the CC treatment.
Therefore, these patients receive the next step therapy such
as gonadotropin therapy, which potentially causes multiple
pregnancies or ovarian hyperstimulation syndrome (OHSS).
To reduce the adverse effect of CC on endometrial
growth, some clinical trials have been tested so far.
Unfer et al. reported that ethinyl estradiol treatment
reversed the antiestrogenic effect of CC on the endomet-
rium [13]. High dose of phytoestrogens [14] and trans-
dermal estradiol [15] were also tested in clinical trials to
improve endometrial thickness in patients undergoing
CC treatment. However, there are no established treat-
ments to reduce or to reverse the adverse effect of
CC on the endometrium.
In this study, we focused on the dosage and timing of
CC treatment. Reduced amounts of CC (half dose) may
diminish the antiestrogenic effect of CC because the
antiestrogenic effect of CC is dose-dependent [16].
Furthermore, since the antiestrogenic effect of standard
CC treatment continues until the late follicular phase
when endometrial growth is still active, early administra-
tion of CC may reduce the adverse effect of CC on the
endometrium. Therefore, this study was undertaken to
investigate whether the modified CC treatments are useful
to prevent a thin endometrium in patients undergoing
CC treatments.Methods
This study (UMIN000007959) is a prospective, randomized
controlled study. The study was conducted according to
guidelines as stated in the Declaration of Helsinki and the
protocol was approved by the Institutional Review Board
of Saiseikai Shimonoseki General Hospital. Informed
consent was obtained from all the patients. Patients
were randomized at the beginning of each cycle by
sealed opaque envelopes containing random generated
numbers. The study was performed at the Saiseikai
Shimonoseki General Hospital during a 4-month period
(May 2012 to September 2012).
Clinical studies
Women with a history of infertility, aged 20–42 yr, first
received a standard CC treatment, 50 mg of CC
(Clomid; Shionogi Co. Ltd., Tokyo, Japan) daily for 5
days starting on the 5th day of the menstrual cycle.
Endometrial thickness and follicular growth were
assessed by vaginal ultrasonography [Aloka ProSound
SSD-3500SV type of instrument and Aloka UST-984-5
(5.0 MHz) vaginal transducer, Aloka Co. Ltd., Tokyo,
Japan]. When follicles reached 18 mm or more in
diameter by ultrasonography, 10,000 IU human chorionic
gonadotropin (HCG, Gonatropin; Asuka Pharmaceutical
Co. Ltd., Tokyo, Japan) was administered to induce ovula-
tion. After a longitudinal view of the uterus was obtained,
the thickness of the endometrium was measured at the
maximum distance between each myometrial/endometrial
interface on the day of HCG injection. When endometrial
thickness was less than 8 mm, the patient was diagnosed
as having a thin endometrium based on our previous
studies [17,18]. The profiles of the patients in this study
including the cause of infertility are shown in Table 1.
There were no difference in the age and causes of infertility
among the three groups. The patients were non-smokers
and free from major medical illness including hyperten-
sion; patients were excluded if they had myoma, adeno-
myosis, congenital uterine anomaly, or ovarian tumors.
Patients were also excluded if they used estrogens,
progesterone, androgens, or had chronic use of any
medication, including nonsteroidal anti-inflammatory
agents. All patients showed no abnormal findings in
the uterine cavity by hysterosalpingography (HSG).
Sixty-six patients who were diagnosed as having a thin
endometrium (< 8 mm) during the standard CC treatment
cycle were recruited in this study. They all showed normal
endometrial thickness (≥ 8 mm) during spontaneous
cycles. To prevent a thin endometrium in the next cycle,
the 66 patients were randomly divided into three groups:
22 patients were given 25 mg/day CC on days 5–9 of the
menstrual cycle (half-dose group), 22 patients were
given 50 mg/day CC on days 1–5 of the menstrual cycle
(early administration group) and 22 patients received a
Table 1 Profiles of the patients in this study
Control (N = 20) Half dose (N = 20) Early administration (N = 21)
Age of women (years) 33.6 ± 4.1 33.3 ± 4.8 33.0 ± 4.8
Causes of infertitlity
Ovulation 8 8 7
PCOS 1 1 2
Male factor 0 1 0
Unexplained 11 10 12
Endometrial thickness during the standard CC treatment cycle (mm) 6.8 ± 0.9 6.4 ± 0.8 6.3 ± 1.1
Data are shown as the mean ± SD.
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follicles reached 18 mm or more in diameter by ultrasonog-
raphy, HCG (10,000 IU) was administered to induce
ovulation. Endometrial thickness and the number of
follicles on the day of HCG injection were also
assessed by ultrasonography. The primary endpoint of
this study was an endometrial thickness. Venous blood was
obtained during the mid-luteal phase (7 days after ovulation)
for the determination of serum progesterone concentrations.
Progesterone concentrations were measured by enzyme
immunoassay (ST AIA-PACK PROG, Tosoh Co., Ltd.,
Japan). The minimal detectable concentration is estimated
to be 0.1 ng/ml. Intra-assay and inter-assay coefficients of
variation were 9.9% and 11.3%, respectively.
Statistical analyses
Statistical analysis was carried out with SPSS for
Windows 13.0. The Mann–Whitney U-test using the
Bonferroni correction, Fisher’s test, and Kruskal Wallis
H-test were employed as appropriate. Differences were
considered to be significant if P < 0.05.
Results
The ages of women in the control, half-dose and early
administration groups (33.6 ± 4.8, 33.8 ± 4.8 and 33.0 ±
4.8, respectively) were not significantly different (Table 1).
None the infertility factors including ovulation disorder,
PCOS, male factors, and unexplained infertility were signifi-
cantly different among the three groups (Table 1). Since
four patients were lost to follow-up and one patient discon-
tinued the study due to anovulation, sixty-one participants
were analyzed (control group: n = 20; early administration
group: n = 21; half-dose group: n = 20) (Figure 1).
Endometrial thickness improved (≥ 8 mm) in 14
patients (70%) in the half-dose group, 19 patients (90%)
in the early administration group and only 3 patients (15%)
in the control group (Table 2). The mean endometrial
thickness was also significantly improved in the half-
dose group (8.6 ± 1.5 mm) and early administration
group (9.4 ± 1.5 mm) compared to the control group
(6.7 ± 1.8 mm) (Table 2). These results indicate thatendometrial growth was significantly improved by the
modified CC treatments.
The days until follicle maturation (days until HCG
injection) were significantly longer in the half-dose
group compared with the other groups (Table 2).
There was no significant difference in the number of
growing (≥ 15 mm) and mature follicles (≥ 18 mm)
among the three groups (Table 2). Serum progesterone
levels during the mid-luteal phase did not differ among
the three groups (Table 2). One case in the half dose
group and 2 cases in the early administration group
became pregnant during the study cycle.
Discussion
We often see patients with a thin endometrium as a
result of standard CC treatment, which is the most
common adverse effect of CC treatment. In fact, our
preliminary study showed that 41 out of 100 women
had a thin endometrium during a standard CC treatment
cycle. Since a thin endometrium is a critical factor of
implantation failure, we have to go to the next-step
therapy such as gonadotropin therapy. Gonadotropin
therapy not only burdens the patient with stress and
medical expense but also can cause multiple pregnancy
and OHSS. Therefore, preventing CC-induced thinning of
the endometrium is important.
Our results showed that 14 out of 20 patients (70%)
improved in endometrial thickness (≥ 8 mm) by half-dose
of CC. This result seems to be inconsistent with a previous
report by Dickey et al. [19] that endometrial thickness,
determined on the day of HCG injection, was not related
to the dose of CC (25–250 mg). This report was based on
retrospective data of the endometrial thi]ckness from all
women who underwent CC treatment while our study
enrolled women whose endometrial thickness was thin
(< 8 mm) in the previous CC treatment cycle.
One may raise a possibility that a half dose of CC
influences follicular growth and luteal function. The half
dose CC treatment delayed follicle maturation compared
with a standard CC treatment. However, the difference was
modest to be permissible. Furthermore, serum progesterone
Figure 1 CONSORT statement flow diagram. In this RCT, sixty-six women who met the inclusion criteria were randomly divided to the three
groups; control group (n-22), early administration group (n = 22), and half-dose group (n = 22).
Takasaki et al. Journal of Ovarian Research 2013, 6:94 Page 4 of 5
http://www.ovarianresearch.com/content/6/1/94levels during the mid-luteal phase did not differ between
the half dose group and the control group, suggesting
that luteal function is not affected by the half dose
CC treatment.
Our results also clearly showed that early administration
of CC improved endometrial thickness in 19 out of 21Table 2 Endometrial thickness, number of follicles and serum
administration groups
Control (N = 20)
Endometrial thickness
Mean ± SD (mm) 6.7 ± 1.8
< 8 mm 17 (85.0%)
≥ 8 mm 3(15.0%)
Days until follicles maturation 12.0 ± 1.5
Number of follicles
≥ 15 mm 1.9 ± 1.0
≥18 mm 1.3 ± 0.5
Serum progesterone (ng/ml) 22.3 ± 11.3
Sixty-one patients were diagnosed as having a thin endometrium (< 8 mm) during
endometrium in the next cycle, the 61 patients were randomly divided into three g
cycle (half-dose group), 21 patients were given 50 mg/day CC on days 1–5 of the m
CC treatment again (control group). Endometrial thickness and number of follicles w
ovulation induction. Venous blood was obtained for the determination of the mean ±
group. (Fisher’s test or Kruskal Wallis H-test).patients (90.4%). The effect of the timing of CC administra-
tion on endometrial thickness has been reported [20-22].
Early administration of CC (100 mg CC; day 1–5) showed
higher endometrial thickness compared with the standard
CC treatment (100 mg CC; day 5–9), but it was not signifi-
cant [20-22]. These studies enrolled all the infertile womenprogesterone levels in the control, half dose and early
Half dose (N = 20) Early administration (N = 21)
8.6 ± 1.5a 9.4 ± 1.5a
6(30.0%) 2(9.6%)
14(70.0%)a 19(90.4%)a
13.6 ± 2.7b 11.6 ± 2.3
1.8 ± 0.9 2.3 ± 0.9
1.4 ± 0.6 1.4 ± 0.6
18.8 ± 7.3 18.8 ± 10.3
the standard clomiphene citrate (CC) treatment cycle. To prevent a thin
roups: 20 patients were given 25 mg/day CC on days 5–9 of the menstrual
enstrual cycle (early administration group) and 20 patients received a standard
as determined by vaginal ultrasonography on the day of HCG injection for
SD. ap < 0.05 versus Control, bp <0.05 versus Control and early administration
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the standard CC treatment. However, our study enrolled
the women whose endometrial thickness was thin (< 8 mm)
in the standard CC treatment cycle. Because early adminis-
tration of CC stimulates follicular growth before dominant
or subdominant follicles are selected, it might increase the
number of growing follicles. However, our result showed
that the number of growing follicles (≥ 15 mm) and
mature follicles (≥ 18 mm) was not increased by early
administration of CC.
Recently, the efficacy of letrozole, which is an aromatase
inhibitor, as an ovulation inducing drug has been reported
[23]. There is a possibility that letrozole can be used as an
alternative ovulation inducing drug to prevent a thin
endometrium. However, it is high cost, and further studies
are needed on the safety of letrozole.Conclusions
The modified CC treatments provide an alternative to pro-
ceeding to gonadotropin therapy for patients with a thin
endometrium as a result of standard CC treatment. The
present study provides important information to prevent thin
endometrium in patients undergoing CC treatment. How-
ever, our ultimate goal of CC treatment for infertile patients
is a successful pregnancy and live birth. Large scale-RCT will
be necessary to evaluate the efficacy of the modified CC
treatment on successful pregnancy in patients with a history
of a thin endometrium caused by the standard CC regimen.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AT designed the study and collected the data. HT analyzed the data and
drafted the first manuscript. TT analyzed the data. KS and HM collected the
data. NS directed the research and drafted the final manuscript. All authors
approved the final manuscript.
Acknowledgments
This work was supported in part by JSPS KAKENHI Grant Number 23791846,
No. 23890140, 24592471, 24791704, 24791705, 25293343, 25462559,
25462560 and 2586145.
Author details
1Department of Obstetrics and Gynecology, Saiseikai Shimonoseki General
Hospital, Yasuokacho 8-5-1, Shimonoseki 759-6603, Japan. 2Department of
Obstetrics and Gynecology, Yamaguchi University Graduate School of
Medicine, Minamikogushi 1-1-1, Ube 755-8505, Japan.
Received: 25 July 2013 Accepted: 20 December 2013
Published: 27 December 2013
References
1. Homburg R: Clomiphene citrate–end of an era? A mini-review.
Hum Reprod 2005, 20:2043–2051.
2. Kousta E, White DM, Franks S: Modern use of clomiphene citrate in
induction of ovulation. Hum Reprod Update 1997, 3:359–365.
3. Dehbashi S, Parsanezhad ME, Alborzi S, Zarei A: Effect of clomiphene
citrate on endometrium thickness and echogenic patterns. Int J Gynaecol
Obstet 2003, 80:49–53.4. Haritha S, Rajagopalan G: Follicular growth, endometrial thickness, and
serum estradiol levels in spontaneous and clomiphene citrate-induced
cycles. Int J Gynaecol Obstet 2003, 81:287–292.
5. Nakamura Y, Ono M, Yoshida Y, Sugino N, Ueda K, Kato H: Effects of
clomiphene citrate on the endometrial thickness and echogenic pattern
of the endometrium. Fertil Steril 1997, 67:256–260.
6. Abdalla HI, Brooks AA, Johnson MR, Kirkland A, Thomas A, Studd JW:
Endometrial thickness: a predictor of implantation in ovum recipients?
Hum Reprod 1994, 9:363–365.
7. Alam V, Bernardini L, Gonzales J, Asch RH, Balmaceda JP: A prospective study
of echographic endometrial characteristics and pregnancy rates during
hormonal replacement cycles. J Assist Reprod Genet 1993, 10:215–219.
8. Gonen Y, Casper RF, Jacobson W, Blankier J: Endometrial thickness and
growth during ovarian stimulation: a possible predictor of implantation
in in vitro fertilization. Fertil Steril 1989, 52:446–450.
9. Richter KS, Bugge KR, Bromer JG, Levy MJ: Relationship between
endometrial thickness and embryo implantation, based on 1,294 cycles
of in vitro fertilization with transfer of two blastocyst-stage embryos.
Fertil Steril 2007, 87:53–59.
10. Amita M, Takahashi T, Tsutsumi S, Ohta T, Takata K, Henmi N, Hara S,
Igarashi H, Takahashi K, Kurachi H: Molecular mechanism of the inhibition
of estradiol-induced endometrial epithelial cell proliferation by clomiphene
citrate. Endocrinology 2010, 151:394–405.
11. Bonhoff AJ, Naether OG, Johannisson E: Effects of clomiphene citrate stimulation
on endometrial structure in infertile women. Hum Reprod 1996, 11:844–849.
12. Sereepapong W, Suwajanakorn S, Triratanachat S, Sampatanukul P,
Pruksananonda K, Boonkasemsanti W, Reinprayoon D: Effects of
clomiphene citrate on the endometrium of regularly cycling women.
Fertil Steril 2000, 73:287–291.
13. Unfer V, Costabile L, Gerli S, Papaleo E, Marelli G, Di Renzo GC: Low dose of
ethinyl estradiol can reverse the antiestrogenic effects of clomiphene
citrate on endometrium. Gynecol Obstet Invest 2001, 51:120–123.
14. Unfer V, Casini ML, Costabile L, Mignosa M, Gerli S, Di Renzo GC: High dose
of phytoestrogens can reverse the antiestrogenic effects of clomiphene
citrate on the endometrium in patients undergoing intrauterine
insemination: a randomized trial. J Soc Gynecol Investig 2004, 11:323–328.
15. Shimoya K, Tomiyama T, Hashimoto K, Moriyama A, Kawamoto A, Tokugawa Y,
Ohashi K, Saji F, Murata Y: Endometrial development was improved by
transdermal estradiol in patients treated with clomiphene citrate.
Gynecol Obstet Invest 1999, 47:251–254.
16. Roumen FJ: Decreased quality of cervix mucus under the influence of
clomiphene: a meta-analysis. Ned Tijdschr Geneeskd 1997, 141:2401–2405.
17. Miwa I, Tamura H, Takasaki A, Yamagata Y, Shimamura K, Sugino N:
Pathophysiologic features of “thin” endometrium. Fertil Steril 2009,
91:998–1004.
18. Takasaki A, Tamura H, Miwa I, Taketani T, Shimamura K, Sugino N: Endometrial
growth and uterine blood flow: a pilot study for improving endometrial
thickness in the patients with a thin endometrium. Fertil Steril 2010,
93:1851–1858.
19. Dickey RP, Taylor SN, Curole DN, Rye PH, Lu PY, Pyrzak R: Relationship of
clomiphene dose and patient weight to successful treatment.
Hum Reprod 1997, 12:449–453.
20. Biljan MM, Mahutte NG, Tulandi T, Tan SL: Prospective randomized
double-blind trial of the correlation between time of administration and
antiestrogenic effects of clomiphene citrate on reproductive end organs.
Fertil Steril 1999, 71:633–638.
21. Dehbashi S, Vafaei H, Parsanezhad MD, Alborzi S: Time of initiation of
clomiphene citrate and pregnancy rate in polycystic ovarian syndrome.
Int J Gynaecol Obstet 2006, 93:44–48.
22. Triwitayakorn A, Suwajanakorn S, Triratanachat S, Sampatanukul P,
Pruksananonda K, Sereepapong W: Effects of initiation day of clomiphene
citrate on the endometrium of women with regular menstrual cycles.
Fertil Steril 2002, 78:102–107.
23. Kar S: Clomiphene citrate or letrozole as first-line ovulation induction
drug in infertile PCOS women: a prospective randomized trial. J Hum
Reprod Sci 2012, 5:262–265.
doi:10.1186/1757-2215-6-94
Cite this article as: Takasaki et al.: A pilot study to prevent a thin
endometrium in patients undergoing clomiphene citrate treatment.
Journal of Ovarian Research 2013 6:94.
